Investor Relations

Investing in Lucid Diagnostics is investing in innovation that has the potential to impact and even transform healthcare.

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

Stock Information
Change
Volume
Market Cap
Stock Information
NASDAQLUCD

Latest News & Updates

Sep 21, 2023

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its...

Sep 7, 2023

Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Lucid...

Sep 6, 2023

Study documents 100 percent concordance between EsoGuard® test results and subsequent medical decision-making Timely results support recently proposed federal legislation which seeks to fund...

VIEW ALL NEWS